GlassScriptPhysician profile
Jennifer E Neely
NPI 1174990501
$4,220.61
in general payments reported to CMS, 2019-2025
46 companies · $822 in 2025
The $822 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $468 · 2022: $639 · 2023: $1,220 · 2024: $1,072 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,114.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.16 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $339.46 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $239.75 | 2023-2024 | Nuzyra |
| Glaxosmithkline, LLC. | $237.86 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $236.48 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $226.83 | 2021-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $224.38 | 2022-2025 | |
| Boston Scientific Corporation | $191.56 | 2021-2025 | General - Pain Management |
| Amgen INC. | $174.73 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $164.12 | 2021-2025 | |
| Painteq LLC | $123.87 | 2024 | Painteq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.20 | 2024-2025 | Jardiance, Ofev |
| Genzyme Corporation | $123.08 | 2022 | |
| Medtronic, INC. | $120.43 | 2022-2024 | Venaseal, Intellis Adaptivestim, Nellcor |
| Lilly USA, LLC | $120.28 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Neely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.